|
Title
|
Publication Date
|
Price
|
Relevance
|
|
COOPER PHARMA LIMITED-Therapeutic Competitors Report
|
Mar 2011 |
£220 |
100% |
|
Cooper Pharma (formerly Cooper Maroc)-Therapeutic Competitors Report
|
Mar 2011 |
£220 |
99% |
|
Wound Treatments - Morocco
|
Aug 2010 |
£600 |
88% |
|
Pharmaceuticals:Analysis of French Companies
|
Aug 2011 |
£495 |
87% |
|
Pharmaceutical Research: Analysis of French Companies
|
Aug 2011 |
£495 |
86% |
|
Pharmaceutical Manufacturers: Analysis of French Companies
|
Aug 2011 |
£495 |
86% |
Pharmacovigilance and Related Developments
2011-2021
|
Aug 2011 |
£1,499 |
82% |
|
The Pharmaceutical Market: Morocco
|
Oct 2011 |
£595 |
81% |
UK Pharmaceutical Wholesalers & Distributors
Business Performance Analysis
|
Aug 2011 |
£350 |
79% |
|
Animal Health: Analysis of French Companies
|
Aug 2011 |
£495 |
78% |
|
Emerging Markets Series: The Pharmaceutical Market of Saudi Arabia
|
Jun 2009 |
£3,605 |
77% |
Cancer Pain Global Clinical Trials Review
Q1, 2011
|
Feb 2011 |
£630 |
76% |
Global Generics Guide: Part 2
Benchmarking country markets and strategic issue
|
Jun 2006 |
£5,500 |
76% |
UK Pharmaceuticals
Business Performance Analysis
|
Aug 2011 |
£350 |
74% |
UK Healthcare
Business Performance Analysis
|
Aug 2011 |
£350 |
73% |
Drug Discovery in India and China
Gaining Momentum with Increasing Pressure on Cost Cutting
|
Feb 2010 |
£2,215 |
73% |
Follicular Lymphoma Global Clinical Trials Review
Q4, 2010
|
Dec 2010 |
£630 |
72% |
Anemia Global Clinical Trials Review
Q1, 2011
|
Jan 2011 |
£630 |
71% |
Mantle Cell Lymphoma Global Clinical Trials Review
Q4, 2010
|
Dec 2010 |
£630 |
71% |
|
IntelliNews - Polish Pharmaceutical Report
|
Jul 2011 |
£160 |
70% |
|
Atrial Fibrillation
|
Aug 2010 |
£2,500 |
68% |
|
RNAi Therapeutics 2008
|
Nov 2007 |
£2,350 |
68% |
MorphoSys AG – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
68% |
|
Pharmaceutical Industry in the United States
|
Jan 2011 |
£220 |
67% |
Pharmaceutical Analytical Services Outsourcing in India
Cost Savings, Product Quality and Shorter Delivery Times are Key Drivers
|
Nov 2010 |
£2,215 |
67% |
|
China Healthcare Reform and Its Impact on IVD, Medical Device and Pharmaceutical Markets
|
Oct 2011 |
£2,215 |
66% |
Chinese Pharmaceutical Market
2012-2022
|
Dec 2011 |
£1,699 |
66% |
Pakistan Pharmaceuticals and Healthcare Report Q2
2011
|
Feb 2011 |
£330 |
66% |
|
Pharmaceutical Industry in China
|
May 2010 |
£125 |
65% |
Advanced Drug Delivery Technologies
Enabling Drug Reformulations and Administration Routes
|
Jan 2011 |
£2,020 |
65% |
